Abstract
In 2017 the FreeStyle Libre flash glucose monitor became available on the NHS Drug Tariff. Clinicians and funders across the UK have had to debate where this device sits in the care of people with diabetes. While some would argue that this device is a replacement for self-monitoring of blood glucose and should therefore be widely available for those who may benefit, the financial climate in the NHS has demanded a more conservative approach. This article considers the current evidence to support the use of the FreeStyle Libre, its position in current and future care pathways and gaps in available evidence.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
